Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2023

01-12-2023 | Rivaroxaban | News item

Safety signal of pemphigoid with use of rivaroxaban

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

The Saudi Food and Drug Authority (SFDA) is advising healthcare professionals to be aware of the safety signal of pemphigoid associated with use of rivaroxaban. …
Literature
Metadata
Title
Safety signal of pemphigoid with use of rivaroxaban
Publication date
01-12-2023
Publisher
Springer International Publishing
Keyword
Rivaroxaban
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51312-8

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Tacrolimus

Case report

Allopurinol

Case report

Azathioprine misuse

Case report

Rituximab

Case report

Allopurinol/cotrimoxazole

Case report

Camrelizumab/tislelizumab/toripalimab